1. Home
  2. MDGL vs SANM Comparison

MDGL vs SANM Comparison

Compare MDGL & SANM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • SANM
  • Stock Information
  • Founded
  • MDGL 2011
  • SANM 1980
  • Country
  • MDGL United States
  • SANM United States
  • Employees
  • MDGL N/A
  • SANM N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • SANM Electrical Products
  • Sector
  • MDGL Health Care
  • SANM Technology
  • Exchange
  • MDGL Nasdaq
  • SANM Nasdaq
  • Market Cap
  • MDGL 6.1B
  • SANM 6.2B
  • IPO Year
  • MDGL N/A
  • SANM 1993
  • Fundamental
  • Price
  • MDGL $427.10
  • SANM $129.02
  • Analyst Decision
  • MDGL Strong Buy
  • SANM Hold
  • Analyst Count
  • MDGL 10
  • SANM 2
  • Target Price
  • MDGL $485.78
  • SANM $94.50
  • AVG Volume (30 Days)
  • MDGL 294.9K
  • SANM 919.5K
  • Earning Date
  • MDGL 10-30-2025
  • SANM 11-03-2025
  • Dividend Yield
  • MDGL N/A
  • SANM N/A
  • EPS Growth
  • MDGL N/A
  • SANM 21.02
  • EPS
  • MDGL N/A
  • SANM 4.67
  • Revenue
  • MDGL $515,547,000.00
  • SANM $8,049,495,000.00
  • Revenue This Year
  • MDGL $394.08
  • SANM $9.01
  • Revenue Next Year
  • MDGL $61.80
  • SANM $7.32
  • P/E Ratio
  • MDGL N/A
  • SANM $27.91
  • Revenue Growth
  • MDGL 3421.98
  • SANM 5.88
  • 52 Week Low
  • MDGL $200.63
  • SANM $63.67
  • 52 Week High
  • MDGL $463.63
  • SANM $160.25
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 50.64
  • SANM 57.46
  • Support Level
  • MDGL $425.60
  • SANM $123.65
  • Resistance Level
  • MDGL $463.63
  • SANM $137.00
  • Average True Range (ATR)
  • MDGL 14.91
  • SANM 6.78
  • MACD
  • MDGL -4.55
  • SANM 1.41
  • Stochastic Oscillator
  • MDGL 20.84
  • SANM 37.66

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About SANM Sanmina Corporation

Sanmina Corp is a provider of integrated manufacturing solutions, components, and after-market services to original equipment manufacturers in the communications networks, storage, industrial, defense and aerospace end markets. The operations are managed as two businesses: Integrated Manufacturing Solutions, which consists of printed circuit board assembly and represents a majority of the firm's revenue; and Components, Products, and Services, which includes interconnect systems and mechanical systems. The firm generates revenue primarily in the United States, China, and Mexico, but has a presence around the world.

Share on Social Networks: